Nuo Therapeutics, Inc. (AURX) SEC Filing 8-K Material Event for the period ending Wednesday, October 24, 2018

Nuo Therapeutics, Inc.

CIK: 1091596 Ticker: AURX

View differences made from one to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..


Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Nuo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AURX
CIK: 1091596
Form Type: 8-K Corporate News
Accession Number: 0001437749-18-018842
Submitted to the SEC: Fri Oct 26 2018 8:30:15 AM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Wednesday, October 24, 2018
Industry: Surgical And Medical Instruments And Apparatus
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: